ZAXINE 550 MG
RIFAXIMIN : 550 MG · DIN 02410702 · SALIX PHARMACEUTICALS INC
Health Canada status: MARKETED
What is ZAXINE?
ZAXINE 550 MG contains RIFAXIMIN : 550 MG. It is listed in the Health Canada Drug Product Database under DIN 02410702, held by SALIX PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZAXINE used for?
Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults; reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02410702 |
|---|---|
| Brand name | ZAXINE |
| Generic / active ingredient | RIFAXIMIN : 550 MG |
| Manufacturer | SALIX PHARMACEUTICALS INC |
| Strength | 550 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A07AA11 RIFAXIMIN |
| AHFS class | 08:12.28.30 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Nov-2013 |
| Original market date | 2013-11-07 00:00:00 |
How is it administered?
HE: 550 mg twice daily. IBS-D: 550 mg three times daily for 14 days. Can be taken with or without food. Tablets should be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), typically 15-30°C for tablets.
How is it supplied?
Bottles of 60 tablets.
Contraindications
Hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any ingredient in the formulation.
Warnings and precautions
Not for systemic infections. Clostridium difficile-associated disease (CDAD) reported. Severe cutaneous adverse reactions (SJS/TEN) reported. Increased exposure in hepatic impairment.
Who else supplies RIFAXIMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIFAXIMIN appears in 16 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.